KOSIN UNIVERSITY COLLEGE OF MEDICINE
Search
- Page Path
- HOME > Search
- A Case of Pulmonary Hypertension Recurred by Graves’ Disease
- Jun Seop Lee, Young Sik Choi, Jae Woo Lee, Jin Seok Yoo, Youn Jung Choi, Dong Hyun Park
- Kosin Med J. 2013;28(2):171-176. Published online January 19, 2013
- DOI: https://doi.org/10.7180/kmj.2013.28.2.171
- 802 View
- 1 Download
-
Abstract
PDF
PubReader 
ePub
A few cases of severe pulmonary hypertension with right heart failure associated with Graves’ disease were reported in the literature. However, cases of pulmonary hypertension with right heart failure recurred by Graves’ disease is very rare. We describe the case of a 60-year old woman who had been treated pulmonary hypertension caused by right pulmonary artery thromboembolism seven years ago. Recently, her pulmonary hypertension with right heart failure was recurred by Graves’ disease. The patient’s symptoms of pulmonary hypertension was resolved after treatment of Graves’ disease.
- A Case of Thyrotoxic Periodic Paralysis Associated with Transient Thyrotoxicosis
- Hye Jung Kwon, Young Sik Choi, Joon Seup Lee, Dong Hyun Park, Yeon Jung Choi, Jin Seok Yoo
- Kosin Med J. 2012;27(2):167-171. Published online December 27, 2012
- DOI: https://doi.org/10.7180/kmj.2012.27.2.167
- 872 View
- 2 Download
-
Abstract
PDFPubReader ePub
Thyrotoxic periodic paralysis is an acute muscle weakness of the limbs associated with hypokalemia. It can occur with any form of thyrotoxicosis. Thyrotoxic periodic paralysis associated with transient thyrotoxicosis due to thyroiditis is very rare. We experienced a case of thyrotoxic periodic paralysis associated with transient thyrotoxicosis. A 39-yr-old man was referred to our hospital because of paralysis of upper and lower extremity. The laboratory results were hypokalemia and mild thyrotoxicosis. A thyroid scan with Tc-99m revealed decreased uptake in the thyroid area compatible with destructive thyroiditis. The paralytic attack did not recur after the patient recovered to euthyroid state.
- The Combination Therapy with Peg-interferon Alfa and Ribavirin for Chronic Hepatitis C in Korea as an Initial Treatment
- Dong Hyun Park, Sang Uk Lee, Jin Seok Yu, Jun Seop Lee, Hye Jung Kwon
- Kosin Med J. 2012;27(2):111-118. Published online December 27, 2012
- DOI: https://doi.org/10.7180/kmj.2012.27.2.111
- 861 View
- 3 Download
-
Abstract
PDFPubReader ePub
Objectives The combination therapy with peginterferon and ribavirin has been used to treat chronic hepatitis C for several years in Korea but there is a few report about the results of the treatment. We evaluated safety and efficacy of the combination therapy with Peg-interferon and ribavirin and analyzed factors that may affect treatment.
Methods Total 72 untreated chronic hepatitis C patients were administered pegylated interferon alfa-2a (180µg/week) or alfa-2b (1.5µg/kg/week) and ribavirin (800 mg/day in genotype 2, 1000-1200 mg/day in genotype 1). Duration of the treatment was 24 weeks in genotype 2 and 48 weeks in genotype 1. Response of the treatment was evaluated by rapid virologic response (RVR), early virologic response (EVR), end treatment virologic response (ETR), sustained virologic response (SVR) and adverse event.
Results The RVR, EVR, ETR, SVR were 61.8%, 82.5%, 88.9% and 80.5% retrospectively. The SVR of genotype 1 was 63.4% and non-genotype 1 was 96.7%. Genotype (Odds ratio: 14.92) was an independent predictor of the SVR. Leukocytopenia, flu-like symptoms, itching, rash and anemia were common adverse events of the combination therapy and if then we reduced dose and there was one case of cessation.
Conclusions The combination therapy with Peg-interferon and ribavirin shows efficacy to the Korean patients with chronic hepatitis C as an initial treatment. Genotypes 2 and 3 were more likely to have a sustained virologic response.
First
Prev
